Clinical trials: Biochemical Recurrence
Prostatic Neoplasm
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
After radical prostatectomy, 30-60% of patients will develop recurrent disease. Salvage radiotherapy, usually at 2 Gy per fraction, is the main treatment option for these patients.
- Trial name
- esSBRT (NCT05667636)
- Testing
- salvage SBRT
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer
Model of Predicting Biochemical Recurrence After Radical Prostate Cancer Based on Pre-treatment PSMA PET / MR Image Features
The purpose of this study is to investigate the predictive value of preoperative 18F-PSMA-1007 PET/MR in the predictive effect of biological recurrence (BCR) after radical prostatectomy (RP) for localized prostate cancer (PCa).
- Trial name
- NCT06604377
- Testing
- Observe
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Ruijin Hospital
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostate Cancer
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
- Trial name
- NCT07569926
- Testing
- fluciclovine (18F)
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
The aim of this study is to test whether adding chemotherapy/cabazitaxel and hormonal/androgen deprivation therapy before surgical removal of your prostate would improve the outcome of salvage surgery for locally recurrent…
- Trial name
- NCT01531205
- Testing
- Androgen Ablation, Cabazitaxel, Salvage Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA <0.70 ng/ml)…
- Trial name
- PROPER2 (NCT04858880)
- Testing
- Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
- Where
- 3 sites in Sweden
- Volunteers
- 374 people
- Sponsor
- Lund University Hospital
Prostate Cancer
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer
Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer
- Trial name
- Sorse (NCT00668083)
- Where
- 12 sites in Italy
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Bladder Cancer, Bladder Cancer, Metastatic
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer.
- Trial name
- TOMBOLA (NCT04138628)
- Testing
- Atezolizumab
- Where
- 5 sites in Denmark
- Volunteers
- 154 people
- Sponsor
- Jørgen Bjerggaard Jensen
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body.
- Conditions
- Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis
- Trial name
- SOAR (NCT03796767)
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Cancer of Prostate
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Obesity and metabolic syndrome are prevalent among prostate cancer patients. Having an elevated insulin level in the blood is associated with a shorter median time to cancer progression and median overall survival in patients…
- Trial name
- BIMET-1 (NCT02614859)
- Testing
- Observation and Bicalutamide, Metformin and Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Prostate Adenocarcinoma, PSA Level Greater Than 0.2
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back.
- Conditions
- Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression
- Trial name
- NCT03501940
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Andrei Iagaru
Prostatic Neoplasms, Prostate Neoplasms
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
This is a prospective, open-label, randomized, cross-over, pilot study of reprogramming therapy in patients with recurrent PCa based on rising PSA only.
- Conditions
- Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
- Trial name
- NCT03572387
- Testing
- 5-Azacitidine, all trans retinoic acid, Lupron
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Adenocarcinoma
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer
This is an expanded access program using 68Ga PSMA-HBED-CC (68Ga-PSMA-11). The primary goal of this expanded access program is to make 68Ga PSMA-11 PET/CT imaging available to patients.
- Trial name
- NCT05415228
- Testing
- 68Ga-PSMA-11
- Sponsor
- Morand Piert, MD
Prostate Cancer
Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.
Prostate cancer biochemical recurrence (BCR) occurs in 20-50% of patients following radical prostatectomy or radiotherapy. Due to significant risk of side effects and uncertainty about the benefits, physicians and patients are…
- Trial name
- RCT-EPAII-BCR (NCT03753334)
- Testing
- MAG-EPA
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer Recurrent
Firmagon (Degarelix) Intermittent Therapy
Men with localized prostate cancer requiring intermittent androgen deprivation therapy for biochemical recurrence following radical therapy will be asked to participate in a phase 4 safety and efficacy clinical trial comparing 10…
- Trial name
- FIT (NCT01512472)
- Testing
- degarelix
- Where
- 15 sites in Canada
- Volunteers
- 144 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
The purpose of this study is to measure the benefit of sorafenib in patients with a rising PSA after treatment with radiation therapy or surgery who are NOT receiving with androgen ablation therapy.
- Trial name
- NCT00694291
- Testing
- Sorafenib
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Prostate Adenocarcinoma, Prostate Cancer
PSMA PET Imaging of Recurrent Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
- Trial name
- NCT03204123
- Testing
- Ga-HBED-iPSMA PET, PET/CT, MRI
- Where
- 7 sites in United States
- Volunteers
- 1,171 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Cancer Recurrence
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
- Trial name
- PERYTON (NCT04642027)
- Testing
- Conventional sEBRT, Hypofractionated sEBRT
- Where
- 13 sites in Netherlands
- Volunteers
- 538 people
- Sponsor
- University Medical Center Groningen
Continence, Potency
Application of Dried Human Amnion Graft to Improve Postprostatectomy Incontinence and Potency
The investigators present a randomized trial of patients undergoing placement of dehydrated human amnion membrane (dHAM) around the neurovascular bundle (NVB) and vesicourethral anastomosis (VUA) during radical retropubic…
- Conditions
- Continence, Potency, Complication, Biochemical Recurrence
- Trial name
- NCT03864939
- Testing
- dHAM, No dHAM
- Where
- Germany
- Volunteers
- 328 people
- Sponsor
- German Centre for Assessment and Evaluation of Innovative Techniques in Medicine